|
Market Closed -
Toronto S.E.
16:00:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 3.870 CAD | -0.51% |
|
-3.73% | -19.71% |
| 09-24 | HLS Therapeutics Gets TSX Acceptance to Increase Normal Course Issuer Bid | MT |
| 08-12 | HLS Therapeutics Inc., Q2 2026 Earnings Call, Aug 12, 2026 |
Company Valuation: HLS Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 82.64 | - | - |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -24.83% | - | - |
| Enterprise Value (EV) | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 82.64 | 82.64 | 82.64 |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -24.83% | 0% | 0% |
| P/E | -28.9x | -9.95x | -3.52x | -4.41x | -9.01x | -13.1x | -38.8x | 30.2x |
| PBR | - | 1.88x | - | 1.22x | - | 1.56x | 1.52x | - |
| PEG | - | -0.1x | -0.2x | 0.2x | 0.2x | 0.3x | 0.6x | -0x |
| Capitalization / Revenue | 6.41x | 3.83x | 1.52x | 1.53x | 1.98x | 1.42x | 1.27x | 1.05x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.42x | 1.27x | 1.05x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 4.34x | 3.66x | 2.51x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -21.2x | -118x | 11.2x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 6.17x | - | - |
| FCF Yield | 3.27% | 7.18% | 16.4% | 9.2% | 15.4% | 16.2% | - | - |
| Dividend per Share 2 | - | - | 0.7398 | - | - | - | - | - |
| Rate of return | - | - | 24.7% | - | - | - | - | - |
| EPS 2 | -0.41 | -0.73 | -0.85 | -0.62 | -0.39 | -0.2067 | -0.07 | 0.09 |
| Distribution rate | - | - | -87% | - | - | - | - | - |
| Net sales 1 | 60.01 | 61.47 | 63.07 | 56.62 | 55.5 | 58.34 | 65.06 | 78.65 |
| EBITDA 1 | 26.33 | 23.83 | 21.05 | 16.65 | 19.62 | 19.03 | 22.57 | 32.9 |
| EBIT 1 | -6.284 | -13.5 | -10.35 | -7.686 | -4.106 | -3.9 | -0.7 | 7.4 |
| Net income 1 | -13.12 | -23.6 | -27.53 | -19.66 | -12.43 | -5.47 | -2.164 | 3.1 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 11.853 | 7.263 | 2.991 | 2.731 | 3.515 | 2.715 | 2.715 | 2.715 |
| Nbr of stocks (in thousands) | 32,451 | 32,384 | 32,071 | 31,793 | 31,274 | 30,442 | - | - |
| Announcement Date | 3/17/22 | 3/16/23 | 3/14/24 | 3/13/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -13.14x | - | - | - | 82.64M | |
| 32.45x | 11.78x | 23.93x | 0.61% | 1,019B | |
| 28.48x | 6.32x | 17.7x | 2.09% | 617B | |
| 33.26x | 7.78x | 16.08x | 2.64% | 464B | |
| 104.98x | 5.87x | 24.89x | 2.36% | 356B | |
| 18.81x | 4.58x | 11.36x | 2.9% | 333B | |
| 19.83x | 5.17x | 12.78x | 3.09% | 267B | |
| 20.02x | 4.17x | 11.86x | 2.13% | 244B | |
| 25.46x | 6.66x | 11.86x | 2.5% | 218B | |
| -43.78x | 6.39x | 24.97x | 2.27% | 179B | |
| Average | 22.64x | 6.52x | 17.27x | 2.29% | 369.73B | |
| Weighted average by Cap. | 31.80x | 7.61x | 18.61x | 1.96% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HLS Stock
- Valuation HLS Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
